Douglas Blayney is a US medical oncologist with a clinical interest in breast cancer, and is internationally recognized for his expertise in oncology quality, value, and the prevention and management of untoward side-effects of cancer treatment. He is a past president of the American Society for Clinical Oncology, and has been medical director at the University of Michigan’s comprehensive cancer center, and at the Stanford Cancer Institute. He has been a member of the FDA’s Oncology Drug Advisory Committee, and has published over seventy peer-reviewed manuscripts.